A phase II GETNE-DUTHY trial tested a combination of durvalumab and tremelimumab in advanced thyroid cancer, according to a reported study update. The trial, led by Capdevila, Hernando, Molina-Cerillo and colleagues, evaluated the checkpoint inhibitor pair as an immunotherapeutic strategy in this setting. The report adds to a growing body of work exploring whether dual checkpoint blockade can improve outcomes in tumors that have limited response durability under standard treatments. For clinicians and sponsors, the key industry question remains how efficacy and safety signals compare with prior thyroid cancer immunotherapy approaches and how biomarkers might refine patient selection in later phases.